European Parliament greenlights Horizon Europe priorities
As a first result of the trilogue on the €100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2175 entries already.
Entries by Thomas Gabrielczyk
Blood routine testing in sepsis and AHF ahead
Pilot routine tests with the vasoactive biomarker bio-ADM confirm clinical test results. Medical leaders back actionable utility of the marker in medical decision-making in septic shock and congestive heart failure.
Biotechpharma UAB expanding production
Lituanian CDMO Biotechpharma UAB has invested €50m in order to expand its production capacity to 5000 litres.
Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.
Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.
Treating diabetes by mimicking gut bacteria effects
Researchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.
Immunic lists at Nasdaq
Chronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies.
Bioengineers to standardise biomanufacturing
Biomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. Synthetic biology groups now wish to create a network of biofoundries that aim to establish reproducibility standards from process design to product purification and – in the long term – intend to switch from cell-based to cell-free bioproduction.
Preventing virus infections in newborns
Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.
Evotec and Indivumed join forces in CRC
Evotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments.
Inhibitor-free DNA Reliability for any Throughput
BioEcho develops single-spin and 96-well kits for the isolation of DNA. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents resulting in increased sensitivity and reliability of downstream analyses. Therefore, the risk of inhibition or complete failure of PCR applications is eliminated. The process does not require washing steps and is significantly faster than commonly used bind-wash-elute methods.